CRBU
Caribou Biosciences, Inc. Healthcare Biotechnology
5/12
Innovation Score
Red Flags (1)
SBC_HIGH (285% of revenue)
Patent Activity
2/3
6 patents found
FUZZY
Cash Runway
1/3
14 months of cash remaining based on current burn rate.
Cash on hand: $117.6M
Cash on hand: $117.6M
Revenue Trajectory
1/3
Revenue: $11.2M
YoY Growth: +1.9%
YoY Growth: +1.9%
Management Quality
1/3
Insider ownership: 4.4%
SBC/Revenue: 285.4%
No reverse splits detected
SBC/Revenue: 285.4%
No reverse splits detected
Key Metrics
Market Cap
$192.4M
Revenue
$11.2M
Revenue Growth (YoY)
+1.9%
Cash on Hand
$117.6M
Cash Runway
14 months
Shares Outstanding
99.2M
Insider Ownership
4.4%
SBC / Revenue
285.4%
Sector / Industry
Healthcare / Biotechnology
Patents (6)
Match type: FUZZY — company name matched partially; verify assignee
- Anti-ROR1 antibody and ROR1-targeting engineered cells
- Method of capturing CRISPR endonuclease cleavage products
- Anti-ROR1 antibody and ROR1-targeting engineered cells
- Engineered cascade components and cascade complexes
- Humanized BCMA antibody and BCMA-CAR-T cells
7-Step Risk Assessment
How CRBU maps to our micro cap methodology:
- Innovation Signal 6 patents identified. This suggests the company is investing in defensible IP.
- Cash Runway Check 14 months of runway. Short runway increases dilution risk — watch for capital raises.
- Revenue Trajectory +1.9% YoY growth on $11.2M revenue. Positive but moderate growth.
- Management Alignment Insiders hold 4.4% of shares. SBC is 285.4% of revenue.
- Competitive Moat Review the company's 10-K for barriers to entry: patents, network effects, switching costs, regulatory approvals. This step requires manual research.
- Catalyst Identification Look for upcoming catalysts: FDA decisions, contract wins, product launches, partnerships. Check recent 8-K filings and earnings transcripts.
- Position Sizing Micro caps carry outsized risk. Consider position sizing relative to conviction level and portfolio concentration. This is a $192.4M company.
Financial Detail
Free Cash Flow
$-62.0M
FCF Yield
-32.2%
Return on Equity
-83.5%
Debt / Equity
26.4%
Gross Margin
N/A
Profit Margin
N/A
Operating Margin
-1096.4%
Price / Book
1.51
Current Ratio
6.22
Dividend Yield
None
Share Count Change (YoY)
N/A
Share Count Change (3yr)
N/A
Quality Flags
Low Debt
Free Cash Flow Trend
Insufficient Data
Consecutive Years FCF Positive
0
Disclaimer: This is an automated screening tool, not investment advice. Micro cap stocks are inherently risky with low liquidity and high volatility. The innovation score is based on publicly available data and may not reflect the full picture. Steps 5-7 of the methodology require your own research. See our full disclaimer.
Last screened: 2026-05-11